ES2185658T3 - Vacuna para la otitis media. - Google Patents

Vacuna para la otitis media.

Info

Publication number
ES2185658T3
ES2185658T3 ES94922428T ES94922428T ES2185658T3 ES 2185658 T3 ES2185658 T3 ES 2185658T3 ES 94922428 T ES94922428 T ES 94922428T ES 94922428 T ES94922428 T ES 94922428T ES 2185658 T3 ES2185658 T3 ES 2185658T3
Authority
ES
Spain
Prior art keywords
fimbrine
dna
vaccine
otitis
codifies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94922428T
Other languages
English (en)
Inventor
Pappachan E Kolattukudy
Lauren O Bakaletz
Tatiana Sirakova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Application granted granted Critical
Publication of ES2185658T3 publication Critical patent/ES2185658T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE HA DESCUBIERTO QUE UNA VACUNA QUE COMPRENDE FIMBRINA, UNA PROTEINA FILAMENTOSA DERIVADA DE LOS APENDICES SUPERFICIALES BACTERIANOS DEL "HAEMOPHILUS INFLUENZAE" ES UTIL EN EL ESTUDIO, LA PREVENCION O LA REDUCCION DE LA SEVERIDAD DE LA OTITIS MEDIA. TAMBIEN SE HA DETERMINADO LA SECUENCIA DE GENES DEL DNA QUE CODIFICA LA FIMBRINA Y LA SECUENCIA DE AMINOACIDO DE LA FIMBRINA. TAMBIEN SE HAN DESARROLLADO VECTORES QUE CONTIENEN EL DNA QUE CODIFICA LA FIMBRINA, Y TRANSFORMANTES QUE HAN SIDO PREPARADOS Y QUE CONTIENEN TALES VECTORES Y QUE EXPRESAN DICHO DNA Y SUMINISTRAN UNA FUENTE DE FIMBRINA PURA.
ES94922428T 1993-05-18 1994-05-12 Vacuna para la otitis media. Expired - Lifetime ES2185658T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6544293A 1993-05-18 1993-05-18

Publications (1)

Publication Number Publication Date
ES2185658T3 true ES2185658T3 (es) 2003-05-01

Family

ID=22062752

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94922428T Expired - Lifetime ES2185658T3 (es) 1993-05-18 1994-05-12 Vacuna para la otitis media.

Country Status (9)

Country Link
US (3) US5766608A (es)
EP (2) EP0699076B1 (es)
JP (1) JP3429313B2 (es)
AT (1) ATE226831T1 (es)
DE (1) DE69431624T2 (es)
DK (1) DK0699076T3 (es)
ES (1) ES2185658T3 (es)
PT (1) PT699076E (es)
WO (1) WO1994026304A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2185658T3 (es) 1993-05-18 2003-05-01 Univ Ohio State Res Found Vacuna para la otitis media.
EP0702516A4 (en) * 1993-06-01 1998-04-22 Life Technologies Inc GENETIC IMMUNIZATION WITH CATIONIC LIPIDS
US5770213A (en) 1994-05-05 1998-06-23 American Cyanamid Company Purified nontypable haemophilus influenzae P5 protein as a vaccine for nontypable haemophilus influenzae infection
US5843464A (en) * 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
GB9812613D0 (en) * 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
EP1829856A3 (en) * 1998-11-12 2009-02-25 Invitrogen Corporation Transfection reagents
JP2002539273A (ja) 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0117762D0 (en) * 2001-07-20 2001-09-12 Glaxosmithkline Biolog Sa Novel compounds
CA2493124C (en) 2002-08-02 2014-04-29 Glaxosmithkline Biologicals S.A. Vaccine
MXPA05004528A (es) 2002-11-01 2005-07-26 Glaxosmithkline Biolog Sa Composicion inmunogenica.
ATE474595T1 (de) 2003-10-02 2010-08-15 Glaxosmithkline Biolog Sa B. pertussis antigene und ihre verwendung bei der vakzinierung
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
US7811591B2 (en) * 2005-07-08 2010-10-12 Nationwide Children's Hospital, Inc. Chimeric vaccine for haemophilus influenzae-induced disease
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
BRPI0620460B8 (pt) 2005-12-22 2021-05-25 Glaxosmithkline Biologicals Sa uso de composição imunogênica para bebês, e, processo para produzir uma vacina
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP1973933B1 (en) 2006-01-17 2020-06-24 Forsgren, Arne A NOVEL SURFACE EXPOSED HAEMOPHILUS INFLUENZAE PROTEIN (PROTEIN E; pE)
BRPI0813644B8 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
WO2009103068A1 (en) 2008-02-15 2009-08-20 Life Technologies Corporation Methods and compositions for shearing of polymers by sonication
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
EP2544714A1 (en) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
US20130156803A1 (en) 2011-06-04 2013-06-20 Rochester General Hospital Research Institute Compositions and methods related to p6
US9855326B2 (en) 2013-03-08 2018-01-02 Research Institute At Nationwide Children's Hospital Transcutaneous haemophilus influenzae vaccine formulations and methods
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB2600654B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel devices
WO2019106192A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
JP7640473B2 (ja) 2019-06-05 2025-03-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
EP4558170A1 (en) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Continuous process for vaccine production

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
DK219084D0 (da) * 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
US5110908A (en) * 1986-12-31 1992-05-05 Praxis Biologics, Inc. Haemophilus influenzae peptides and proteins
ES2185658T3 (es) 1993-05-18 2003-05-01 Univ Ohio State Res Found Vacuna para la otitis media.

Also Published As

Publication number Publication date
JPH09500104A (ja) 1997-01-07
DK0699076T3 (da) 2003-03-03
DE69431624D1 (de) 2002-12-05
JP3429313B2 (ja) 2003-07-22
WO1994026304A1 (en) 1994-11-24
EP0699076B1 (en) 2002-10-30
US6562349B1 (en) 2003-05-13
ATE226831T1 (de) 2002-11-15
US5766608A (en) 1998-06-16
EP1300156A3 (en) 2003-05-07
US6030626A (en) 2000-02-29
PT699076E (pt) 2003-03-31
DE69431624T2 (de) 2003-07-10
EP0699076A1 (en) 1996-03-06
EP0699076A4 (en) 1999-09-08
EP1300156A2 (en) 2003-04-09

Similar Documents

Publication Publication Date Title
DE69431624D1 (de) Impfstoff gegen mittelohrentzündung
WO1998027204A3 (en) AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors
ATE177757T1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
GB9108652D0 (en) Immunoreactive compounds
GR3026658T3 (en) Hydrazino-type radionuclide chelators having an n 3?s configuration
ES2177476T1 (es) Genes de corynebacterium glutamicum que codifican proteinas implicadas en la sintesis de la membrana y el transporte a traves de la membrana.
ES2176128T1 (es) Genes de corynebacterium glutamicum que codifican proteinas implicadas en la homeostasis y la adaptacion.
NO965487D0 (no) Optiske hvitemidler
AU7528894A (en) Hydrazino-type n2s2 chelators
EP0610517A4 (en) Dna coding for decarbamylase improved in thermostability and use thereof.
EP0982988A4 (en) IN KEY PURE ZONULIN AS A PHYSIOLOGICAL MODULATOR OF "TIGHT JUNCTIONS" IN MAMMALS
NO940736D0 (no) DNA sekvenser som koder for gelonin polypeptid
EP0754229A1 (en) Alfamin: a human serum albumin-like protein
BR9811850A (pt) Expressão recombinante de peptìdeo c de insulina
HUP0104825A2 (hu) Gének, fehérjék és alkalmazásuk
IL122606A (en) (S)-hydroxa-nitrile-lyase
HUT77029A (hu) A GAP-protein SH3 doménjéhez kötődni képes peptidek, ezeket kódoló nukleotidszekvenciák és előállításuk és alkalmazásuk
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
DK0990703T3 (da) Nyt polypeptid, DNA, som koder herfor, samt anvendelse heraf
ATE210184T1 (de) Ungespleisste varianten des gp350/220
ATE214427T1 (de) Chimäre msp und daf proteine mit einem telloberflächenlokalisierendem domän
DK0789764T3 (da) Ny familie af proteaseinhibitorer og andre biologisk aktive substanser
DK0946590T3 (da) Dihydroxypropylcysteinpeptid og middel, der indeholder dette peptid
YU200091A (sh) Delecioni mutanti ahasarezistentni na herbicide
WO1992011367A3 (en) Lipid receptors for microorganisms and corresponding adhesins, dna sequences encoding adhesins, and use thereof